Rybelsus 3 Mg, 7 Mg, 14 Mg 3 mg, 7 mg, 14 mg Tablets
PDF Leaflet Revision Date: 03 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adults with insufficiently controlled type 2 diabetes mellitus.
Dosage (summary)
Starting dose: 3 mg once daily for 1 month, then 7 mg once daily; may increase to 14 mg after 1 month.
Onset of Action / Duration
Onset: 1 week, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential risks.
Key Drug Interactions
- Warfarin
- Levothyroxine
- SGLT2 inhibitors
- Sulfonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Hypersensitivity to semaglutide
Common side effects
- Nausea
- Diarrhoea
- Vomiting
- Hypoglycaemia
- Fatigue
Counselling Points
- Take on an empty stomach
- Wait 30 mins before eating or taking other medications
- Monitor for signs of pancreatitis
Serious warnings
- Risk of thyroid C-cell tumors
- Acute pancreatitis
- Gastrointestinal effects leading to dehydration
Important Disclaimer
The Rybelsus 3 Mg, 7 Mg, 14 Mg 3 mg, 7 mg, 14 mg Tablets professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
